Publications by authors named "S W Luger"
Venetoclax with hypomethylating agents (HMA) is the standard of care for acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy and is associated with tumor lysis syndrome (TLS). TLS prophylaxis and the use of Cairo Bishop versus Howard diagnostic criteria are not standardized. Here we report TLS prophylaxis and incidence in a retrospective cohort of 100 consecutive AML patients treated with venetoclax and HMA.
View Article and Find Full Text PDFArticle Synopsis
- - In the last decade, significant advancements have been made in treating adults with newly diagnosed B-cell acute lymphoblastic leukaemia, driven by better understanding of the disease and innovative treatment strategies like incorporating immunotherapy and tyrosine kinase inhibitors.
- - Despite these advancements, adults still have worse outcomes compared to children, facing higher rates of treatment failure and complications, leading to ongoing use of transplant consolidation for high-risk cases.
- - The article emphasizes the need for new trial designs to further improve treatment strategies and personalize care for adults with acute lymphoblastic leukaemia, sharing insights from practices across Europe and other continents.
Article Synopsis
- The study investigates the combination of venetoclax (VEN) and vincristine (L-VCR) for patients with relapsed or refractory acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL).
- In a dose escalation trial with 18 patients, the maximum tolerated dose (MTD) of the drug combination was determined to be VEN at 600 mg, with significant adverse events reported in 89% of participants.
- The preliminary results showed a 22% complete response rate, with some patients achieving no measurable residual disease, indicating potential efficacy for this treatment approach.
Article Synopsis
- - The NCCN Guidelines for acute lymphoblastic leukemia (ALL) offer management recommendations that prioritize classifying ALL subtypes using immunophenotype and cytogenetic/molecular markers.
- - The guidelines emphasize risk assessment and stratification to tailor therapy for both Ph-positive and Ph-negative ALL, specifically addressing treatment for adolescent, young adult, and adult patients.
- - This excerpt highlights treatment recommendations specifically for adults newly diagnosed with Ph-negative ALL, grounded in the latest evidence-based research.
Acute myeloid leukemia (AML) is a rapidly progressive malignancy without effective therapies for refractory disease. So far, chimeric antigen receptor (CAR) T cell therapy in AML has not recapitulated the efficacy seen in B cell malignancies. Here we report a pilot study of autologous anti-CD123 CAR T cells in 12 adults with relapsed or refractory AML.
View Article and Find Full Text PDF